Basic Information
| LncRNA/CircRNA Name | MIR22HG |
| Synonyms | MIR22HG, C17orf91 |
| Region | GRCh38_17:1711493-1717174 |
| Ensemble | ENSG00000186594 |
| Refseq | NR_028502 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot etc. |
| Sample | endometrial cancer tissues, cell line (HEC-1 A and KLE) |
| Expression Pattern | down-regulated |
| Function Description | qRT-PCR showed that MIR22HG expression was significantly downregulated in EC tissues. In vitro function assays showed that increased MIR22HG expression significantly inhibited EC cells proliferation, induced EC cells apoptosis, and arrested EC cells in G0/G1 phase. Furthermore, miR-141-3p was identified and confirmed to be the target of MIR22HG. Subsequently, DAPK1 was confirmed to be regulated by MIR22HG and miR-141-3p, and could play a positive role in inhibiting EC cells proliferation. |
| Pubmed ID | 29775889 |
| Year | 2018 |
| Title | LncRNA MIR22HG negatively regulates miR-141-3p to enhance DAPK1 expression and inhibits endometrial carcinoma cells proliferation. |
External Links
| Links for MIR22HG | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |